Αποτελέσματα Αναζήτησης
Our enhanced FDA calendar integrates PDUFA dates, clinical trial primary completion dates, and working capital runway estimates into a single timeline that covers companies publicly traded in the U.S. facing upcoming PDUFA dates.
- Membership Levels
Join FDA Tracker Today! Level Initial Payment Subscription...
- Trial Tracker
Trial Tracker Demo. This limited demo only displays Phase 3...
- Membership Levels
New Drug Application (NDA) 21-686, submitted by AstraZeneca LP (AstraZeneca), requests approval for the use of EXANTA® (ximelagatran) Tablets as: An oral 24-mg twice daily (bid) fixed dose for the long-term secondary prevention of venous thromboembolism (VTE) after standard treatment for an episode of acute VTE An oral 36-mg bid fixed dose ...
Exanta FDA Approval Status. FDA Approved: No. Brand name: Exanta. Generic name: ximelagatran. Company: AstraZeneca. Treatment for: Prevention of Thromboembolism in Atrial Fibrillation.
approval for the use of EXANTA® (ximelagatran) Tablets as: œ An oral 24-mg twice daily (bid) fixed dose for the long-term secondary prevention of venous thromboembolism (VTE) after standard treatment for an episode of acute
Ximelagatran (Exanta or Exarta, H 376/95) is an anticoagulant that has been investigated extensively as a replacement for warfarin [1] that would overcome the problematic dietary, drug interaction, and monitoring issues associated with warfarin therapy.
Our Free FDA Calendar is a daily updated tool that tracks future catalysts and key dates across biotech and pharma companies, including clinical trials, regulatory events, and PDUFA dates, designed to inform on stock-moving events
Our FDA Calendar is designed to provide you with future catalysts across biotech & pharma companies, updated on a daily basis for all companies we cover.
